docetaxel for metastatic prostate cancer

Ads
related to: docetaxel for metastatic prostate cancer
New ENHERTU® Indication - ENHERTU® Patient Data

www.enhertu.com
(fam-trastuzumab deruxtecan-nxki). Read The PI & Boxed Warnings on Patient Website. Talk to Your Doctor About ENHERTU® as a Possible Treatment.
ENHERTU® Safety Info
Important Side Effect Information

for Patients and Caregivers.

ENHERTU® Resources
Access Free Patient Resources Like

a Downloadable Brochure.

ENHERTU® Information
Learn More About ENHERTU® and How

it is Thought to Work.

ENHERTU® Data
Access Important Data on How

ENHERTU® Performed in Studies.
New ENHERTU® Indication - Healthcare Professional Site

www.enhertuhcp.com
(fam-trastuzumab deruxtecan-nxki). Read The PI & Boxed Warnings on Physician Website. Learn About How ENHERTU® May Help Your Patients. Approved For a New Indication.
New Approval Info
Efficacy Of ENHERTU®
Common Adverse Reactions
Prep & Admin
About ENHERTU®

Search results

- FDA Approves Expanded Use For Bayer's Prostate Cancer Drug
  Benzinga via Yahoo Finance· 2 years ago
  The FDA approved Bayer AG's (OTC: BAYRY) supplemental marketing application for Nubeqa...
- Pfizer, Astellas Tout Positive Xtandi Data To Potentially Expand Label For The Prostate Cancer Drug
  Benzinga via Yahoo Finance· 1 year ago
  https://cdn.benzinga.com/files/images/story/2023/03/17/pfe.png?optimize=medium&dpr=2&auto=webp&crop=1200%2C800 Pfizer Inc (NYSE: PFE) and Astellas Pharma Inc (OTC: ALPMY) released topline results ...
- Merck's Two Keytruda Combo Cancer Trials Miss Primary Goal
  Benzinga via Yahoo Finance· 2 years ago
  Merck & Co Inc's (NYSE: MRK) Phase 3 KEYNOTE-921 trial of Keytruda combined with chemotherapy...
- Q2 2023 PDS Biotechnology Corp Earnings Call
  Thomson Reuters StreetEvents via Yahoo Finance· 9 months ago
  Participants Frank K. Bedu-Addo; President, CEO & Director; PDS Biotechnology Corporation Lauren V. Wood; Chief Medical Officer; PDS Biotechnology Corporation Matthew C. Hill; CFO, Principal ...
- MacroGenics, Inc. (NASDAQ:MGNX) Q1 2023 Earnings Call Transcript
  Insider Monkey via Yahoo Finance· 1 year ago
  MacroGenics, Inc. (NASDAQ:MGNX) Q1 2023 Earnings Call Transcript May 9, 2023 Operator: Good...
- Bayer (BAYRY) Loses 28% in 2023: What to Expect in 2024?
  Zacks via Yahoo Finance· 5 months ago
  Bayer AG BAYRY put up a dismal performance in 2023, even though other players in the large-cap...
- Merck's Keytruda Combo Therapy Less Effective Than Chemo In Lung Cancer Patients, Data Shows
  Benzinga via Yahoo Finance· 1 year ago
  https://cdn.benzinga.com/files/images/story/2023/03/17/mrk.png?optimize=medium&dpr=2&auto=webp&crop=1200%2C800 Merck & Co Inc's (NYSE: MRK) MK-7684A failed the open-label portion of a Phase ...
- Exelixis (EXEL) Reports Data from CONTACT-01, QUARTZ-101 Study
  Zacks via Yahoo Finance· 1 year ago
  Exelixis (EXEL) announces that the phase III study, CONTACT-01, did not meet its primary endpoint....
- Why MacroGenics Stock Inched Higher on Monday
  Motley Fool· 1 year ago
  The stock of cancer-focused biotech MacroGenics (NASDAQ: MGNX) was off to a good start this week. Analysts are continuing to revise their takes on...
- Why Shares of MacroGenics Climbed Thursday
  Motley Fool· 1 year ago
  Shares of MacroGenics (NASDAQ: MGNX) were up 14.5% in early trading Thursday thanks to a strong 2022 earnings report that it released after the market...